The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Chronic Elevation of Parathyroid Hormone in Mice Reduces Expression of Sclerostin by Osteocytes: A Novel Mechanism for Hormonal Control of Osteoblastogenesis
Open accessAbstract
Both chronic excess of PTH, as in hyperparathyroidism, and intermittent elevation of PTH (by daily injections) increase the number of osteoblasts; albeit, the former is associated with bone catabolism and the later with bone anabolism. Intermittent PTH increases osteoblast number by attenuating osteoblast apoptosis, an effect that requires the transcription factor Runx2. However, chronic elevation of PTH does not affect osteoblast apoptosis because it stimulates the proteasomal degradation of Runx2. Here, we studied the effects of PTH on Sost, a Runx2 target gene expressed in osteocytes (former osteoblasts embedded in the bone matrix), which antagonizes the pro-osteoblastogenic actions of bone morphogenetic proteins and Wnts. We report that continuous infusion of PTH to mice for 4 d decreased Sost mRNA expression in vertebral bone by 80–90%. This effect was accompanied by a comparable reduction of sclerostin, the product of Sost, in osteocytes, as determined by quantitative immunoblot analysis of bone extracts and by immunostaining. In contrast, a single injection of PTH caused a transient 50% reduction in Sost mRNA at 2 h, but four daily injections had no effect on Sost mRNA or sclerostin. PTH strongly decreased Sost expression in osteocytes formed in primary cultures of neonatal murine calvaria cells as well as in osteocytic MLO-A5 cells, demonstrating a direct effect of PTH on this cell type. These results, together with evidence that sclerostin antagonizes bone morphogenetic proteins and Wnts, strongly suggest that suppression of Sost by PTH represents a novel mechanism for hormonal control of osteoblastogenesis mediated by osteocytes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Osf2/Cbfa1: A Transcriptional Activator of Osteoblast Differentiation
Ducy, P., Zhang, R., Geoffroy, V., Ridall, A. L., & Karsenty, G. (1997) · Cell · doi:10.1016/s0092-8674(00)80257-3 · Cited by 4,246
Manolagas, S. C. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.2.0395 · Cited by 2,568
Self-citationSclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling
Li, X., Zhang, Y., Kang, H., Liu, W., Liu, P., Zhang, J., Harris, S. E., & Wu, D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413274200 · Cited by 1,366
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147
Nongenotropic, Sex-Nonspecific Signaling through the Estrogen or Androgen Receptors
Kousteni, S., Bellido, T., Plotkin, L. I., O'Brien, C. A., Bodenner, D. L., Han, L., Han, K., DiGregorio, G. B., Katzenellenbogen, J. A., Katzenellenbogen, B. S., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00268-9 · Cited by 1,113
Self-citationOsteocyte control of bone formation via sclerostin, a novel BMP antagonist
Winkler, D. G. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg599 · Cited by 1,112
Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone
Jilka, R. L., Weinstein, R. S., Bellido, T., Roberson, P., Parfitt, A. M., & Manolagas, S. C. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6610 · Cited by 1,043
Self-citationBrunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318811 · Cited by 1,011
van Bezooijen, R. L., Roelen, B. A. J., Visser, A., van der Wee-Pals, L., de Wilt, E., Karperien, M., Hamersma, H., Papapoulos, S. E., ten Dijke, P., & Löwik, C. W. G. M. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031454 · Cited by 892
Cited by
Bonewald, L. F. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.320 · Cited by 2,287
WNT signaling in bone homeostasis and disease: From human mutations to treatments
Baron, R., & Kneissel, M. (2013) · Nature Medicine · doi:10.1038/nm.3074 · Cited by 2,093
Mechanical Stimulation of Bone in Vivo Reduces Osteocyte Expression of Sost/Sclerostin
Robling, A. G., Niziolek, P. J., Baldridge, L. A., Condon, K. W., Allen, M. R., Alam, I., Mantila, S. M., Gluhak-Heinrich, J., Bellido, T. M., Harris, S. E., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m705092200 · Cited by 1,350
Self-citationManolagas, S. C. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0024 · Cited by 1,200
Self-citationBuilding strong bones: molecular regulation of the osteoblast lineage
Long, F. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3254 · Cited by 1,141
The Osteocyte: An Endocrine Cell … and More
Dallas, S. L., Prideaux, M., & Bonewald, L. F. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1026 · Cited by 1,042
Growth Hormone, Insulin-Like Growth Factors, and the Skeleton
Giustina, A., Mazziotti, G., & Canalis, E. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0036 · Cited by 914
Molecular and cellular mechanisms of the anabolic effect of intermittent PTH
Jilka, R. L. (2007) · Bone · doi:10.1016/j.bone.2007.03.017 · Cited by 720
Self-citationKenkre, J., & Bassett, J. (2018) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563218759371 · Cited by 693
Mechanisms of Anabolic Therapies for Osteoporosis
Canalis, E., Giustina, A., & Bilezikian, J. P. (2007) · New England Journal of Medicine · doi:10.1056/nejmra067395 · Cited by 668
Irisin Mediates Effects on Bone and Fat via αV Integrin Receptors
Kim, H., Wrann, C. D., Jedrychowski, M., Vidoni, S., Kitase, Y., Nagano, K., Zhou, C., Chou, J., Parkman, V.-J. A., Novick, S. J., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.025 · Cited by 638
“, 2017) and as such these cells have become a prime target for anabolic osteoporotic therapies such as parathyroid hormone and monoclonal anti-sclerostin antibodies (Bellido et al., 2005; Keller and Kneissel, 2005; Li et al., 2009; Ominsky et al., 2010).”
Targeting the Wnt/β-Catenin Pathway to Regulate Bone Formation in the Adult Skeleton
Baron, R., & Rawadi, G. (2007) · Endocrinology · doi:10.1210/en.2007-0270 · Cited by 584
Pederson, L., Ruan, M., Westendorf, J. J., Khosla, S., & Oursler, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805133106 · Cited by 556
Parathyroid hormone: anabolic and catabolic actions on the skeleton
Silva, B. C., & Bilezikian, J. P. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.03.005 · Cited by 557
Robling, A. G., & Bonewald, L. F. (2020) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021119-034332 · Cited by 539
Osteoimmunology: The conceptual framework unifying the immune and skeletal systems
Okamoto, K., Nakashima, T., Shinohara, M., Negishi-Koga, T., Komatsu, N., Terashima, A., Sawa, S., Nitta, T., & Takayanagi, H. (2017) · Physiological Reviews · doi:10.1152/physrev.00036.2016 · Cited by 534
Understanding the Bone in Cancer Metastasis
Fornetti, J., Welm, A. L., & Stewart, S. A. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3618 · Cited by 526
Sims, N. A., & Gooi, J. H. (2008) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2008.07.016 · Cited by 513
Sclerostin Stimulates Osteocyte Support of Osteoclast Activity by a RANKL-Dependent Pathway
Wijenayaka, A. R., Kogawa, M., Lim, H. P., Bonewald, L. F., Findlay, D. M., & Atkins, G. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025900 · Cited by 503
Tu, X., Rhee, Y., Condon, K. W., Bivi, N., Allen, M. R., Dwyer, D., Stolina, M., Turner, C. H., Robling, A. G., Plotkin, L. I., et al. (2012) · Bone · doi:10.1016/j.bone.2011.10.025 · Cited by 459
Self-citationRole and mechanism of action of sclerostin in bone
Delgado-Calle, J., Sato, A. Y., & Bellido, T. (2017) · Bone · doi:10.1016/j.bone.2016.10.007 · Cited by 443
Self-citationLavi-Moshayoff, V., Wasserman, G., Meir, T., Silver, J., & Naveh-Many, T. (2010) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00360.2010 · Cited by 441
WNT–β-catenin signalling — a versatile player in kidney injury and repair
Schunk, S. J., Floege, J., Fliser, D., & Speer, T. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00343-w · Cited by 427
Transforming growth factor‐β in stem cells and tissue homeostasis
Xu, X., Zheng, L., Yuan, Q., Zhen, G., Crane, J. L., Zhou, X., & Cao, X. (2018) · Bone Research · doi:10.1038/s41413-017-0005-4 · Cited by 414
Osteoblast and osteocyte: Games without frontiers
Capulli, M., Paone, R., & Rucci, N. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.05.003 · Cited by 413
Sclerostin and Dickkopf-1 as Therapeutic Targets in Bone Diseases
Ke, H. Z., Richards, W. G., Li, X., & Ominsky, M. S. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1060 · Cited by 402
Update on Wnt signaling in bone cell biology and bone disease
Monroe, D. G., McGee-Lawrence, M. E., Oursler, M. J., & Westendorf, J. J. (2012) · Gene · doi:10.1016/j.gene.2011.10.044 · Cited by 392
Control of Bone Mass and Remodeling by PTH Receptor Signaling in Osteocytes
O'Brien, C. A., Plotkin, L. I., Galli, C., Goellner, J. J., Gortazar, A. R., Allen, M. R., Robling, A. G., Bouxsein, M., Schipani, E., Turner, C. H., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002942 · Cited by 390
Self-citationOsteocyte-Driven Bone Remodeling
Bellido, T. (2014) · Calcified Tissue International · doi:10.1007/s00223-013-9774-y · Cited by 384
Self-citationOsteocyte-Related Cytokines Regulate Osteoclast Formation and Bone Resorption
Kitaura, H., Marahleh, A., Ohori, F., Noguchi, T., Shen, W.-R., Qi, J., Nara, Y., Pramusita, A., Kinjo, R., & Mizoguchi, I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145169 · Cited by 380
Building bone to reverse osteoporosis and repair fractures
Khosla, S., Westendorf, J. J., & Oursler, M. J. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33612 · Cited by 353
Bone morphogenetic proteins and their antagonists
Gazzerro, E., & Canalis, E. (2007) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-006-9000-6 · Cited by 338
Sclerostin: Current Knowledge and Future Perspectives
Moester, M. J. C., Papapoulos, S. E., Löwik, C. W. G. M., & van Bezooijen, R. L. (2010) · Calcified Tissue International · doi:10.1007/s00223-010-9372-1 · Cited by 332
Mirza, F. S., Padhi, I. D., Raisz, L. G., & Lorenzo, J. A. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2283 · Cited by 311
Walker, E. C., McGregor, N. E., Poulton, I. J., Solano, M., Pompolo, S., Fernandes, T. J., Constable, M. J., Nicholson, G. C., Zhang, J.-G., Nicola, N. A., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40568 · Cited by 300
Hormones and Disorders of Mineral Metabolism
Bringhurst, F. R., Demay, M. B., & Kronenberg, H. M. (2011) · Williams Textbook of Endocrinology · doi:10.1016/b978-1-4377-0324-5.00028-6 · Cited by 298
PTH and PTHrP signaling in osteoblasts
Datta, N. S., & Abou-Samra, A. B. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2009.02.012 · Cited by 295
The Wnt Inhibitor Sclerostin Is Up-regulated by Mechanical Unloading in Osteocytes in Vitro
Spatz, J. M., Wein, M. N., Gooi, J. H., Qu, Y., Garr, J. L., Liu, S., Barry, K. J., Uda, Y., Lai, F., Dedic, C., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.628313 · Cited by 290
Osteocyte RANKL: New insights into the control of bone remodeling
Xiong, J., & O'Brien, C. A. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1547 · Cited by 287
Self-citationLocal communication on and within bone controls bone remodeling
Henriksen, K., Neutzsky-Wulff, A. V., Bonewald, L. F., & Karsdal, M. A. (2009) · Bone · doi:10.1016/j.bone.2009.03.671 · Cited by 282
Osteocytes mediate the anabolic actions of canonical Wnt/β-catenin signaling in bone
Tu, X., Delgado-Calle, J., Condon, K. W., Maycas, M., Zhang, H., Carlesso, N., Taketo, M. M., Burr, D. B., Plotkin, L. I., & Bellido, T. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1409857112 · Cited by 276
Self-citationBivi, N., Condon, K. W., Allen, M. R., Farlow, N., Passeri, G., Brun, L. R., Rhee, Y., Bellido, T., & Plotkin, L. I. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.548 · Cited by 261
Self-citationCirculating Sclerostin Levels and Bone Turnover in Type 1 and Type 2 Diabetes
Gennari, L., Merlotti, D., Valenti, R., Ceccarelli, E., Ruvio, M., Pietrini, M. G., Capodarca, C., Franci, M. B., Campagna, M. S., Calabrò, A., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2958 · Cited by 272
Kansara, M., Tsang, M., Kodjabachian, L., Sims, N. A., Trivett, M. K., Ehrich, M., Dobrovic, A., Slavin, J., Choong, P. F. M., Simmons, P. J., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37175 · Cited by 272
Rhee, Y., Bivi, N., Farrow, E., Lezcano, V., Plotkin, L. I., White, K. E., & Bellido, T. (2011) · Bone · doi:10.1016/j.bone.2011.06.025 · Cited by 262
Self-citationThe osteocyte as a signaling cell
Delgado-Calle, J., & Bellido, T. (2022) · Physiological Reviews · doi:10.1152/physrev.00043.2020 · Cited by 261
Self-citationWeitzmann, M. N. (2013) · Scientifica · doi:10.1155/2013/125705 · Cited by 259
A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair
Florio, M., Gunasekaran, K., Stolina, M., Li, X., Liu, L., Tipton, B., Salimi-Moosavi, H., Asuncion, F. J., Li, C., Sun, B., et al. (2016) · Nature Communications · doi:10.1038/ncomms11505 · Cited by 257
Metastatic bone disease: Pathogenesis and therapeutic options
D'Oronzo, S., Coleman, R., Brown, J., & Silvestris, F. (2019) · Journal of Bone Oncology · doi:10.1016/j.jbo.2018.10.004 · Cited by 255
Sabbagh, Y., Graciolli, F. G., O'Brien, S., Tang, W., dos Reis, L. M., Ryan, S., Phillips, L., Boulanger, J., Song, W., Bracken, C., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1630 · Cited by 254
Woo, S. M., Rosser, J., Dusevich, V., Kalajzic, I., & Bonewald, L. F. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.465 · Cited by 243
PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling
Rhee, Y., Allen, M. R., Condon, K., Lezcano, V., Ronda, A. C., Galli, C., Olivos, N., Passeri, G., O'Brien, C. A., Bivi, N., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.304 · Cited by 208
Self-citationParathyroid hormone-dependent bone formation requires butyrate production by intestinal microbiota
Li, J.-Y., Yu, M., Pal, S., Tyagi, A. M., Dar, H., Adams, J., Weitzmann, M. N., Jones, R. M., & Pacifici, R. (2020) · Journal of Clinical Investigation · doi:10.1172/jci133473 · Cited by 198
A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling
Peterson, M. C., & Riggs, M. M. (2010) · Bone · doi:10.1016/j.bone.2009.08.053 · Cited by 198
Effects of PTH on osteocyte function
Bellido, T., Saini, V., & Pajevic, P. D. (2013) · Bone · doi:10.1016/j.bone.2012.09.016 · Cited by 196
Saini, V., Marengi, D. A., Barry, K. J., Fulzele, K. S., Heiden, E., Liu, X., Dedic, C., Maeda, A., Lotinun, S., Baron, R., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.441360 · Cited by 167
Vlashi, R., Zhang, X., Wu, M., & Chen, G. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.07.011 · Cited by 165
HDAC5 Controls MEF2C-Driven Sclerostin Expression in Osteocytes
Wein, M. N., Spatz, J., Nishimori, S., Doench, J., Root, D., Babij, P., Nagano, K., Baron, R., Brooks, D., Bouxsein, M., et al. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2381 · Cited by 158
Grethen, E., Hill, K. M., Jones, R., Cacucci, B. M., Gupta, C. E., Acton, A., Considine, R. V., & Peacock, M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2280 · Cited by 136
Bellido, M., Lugo, L., Roman-Blas, J. A., Castañeda, S., Calvo, E., Largo, R., & Herrero-Beaumont, G. (2011) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2011.07.003 · Cited by 134
The Osteoblast to Osteocyte Transition: Epigenetic Changes and Response to the Vitamin D3Hormone
St. John, H. C., Bishop, K. A., Meyer, M. B., Benkusky, N. A., Leng, N., Kendziorski, C., Bonewald, L. F., & Pike, J. W. (2014) · Molecular Endocrinology · doi:10.1210/me.2014-1091 · Cited by 127
Osteocytic oxygen sensing controls bone mass through epigenetic regulation of sclerostin
Stegen, S., Stockmans, I., Moermans, K., Thienpont, B., Maxwell, P. H., Carmeliet, P., & Carmeliet, G. (2018) · Nature Communications · doi:10.1038/s41467-018-04679-7 · Cited by 126
Ben-awadh, A. N., Delgado-Calle, J., Tu, X., Kuhlenschmidt, K., Allen, M. R., Plotkin, L. I., & Bellido, T. (2014) · Endocrinology · doi:10.1210/en.2014-1046 · Cited by 114
Self-citationGooi, J. H., Pompolo, S., Karsdal, M. A., Kulkarni, N. H., Kalajzic, I., McAhren, S. H. M., Han, B., Onyia, J. E., Ho, P. W. M., Gillespie, M. T., et al. (2010) · Bone · doi:10.1016/j.bone.2010.02.018 · Cited by 117
“proposed to explain the PTH anabolic effect, including direct actions favoring committed osteoblast precursor differentiation [3], inhibition of osteoblast apoptosis [4], and more recently, reduced production of the osteocyte-derived anti-anabolic agent sclerostin [5, 6].”
BackgroundMoriishi, T., Fukuyama, R., Ito, M., Miyazaki, T., Maeno, T., Kawai, Y., Komori, H., & Komori, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040143 · Cited by 105
Role of the RANK/RANKL/OPG and Wnt/β-Catenin Systems in CKD Bone and Cardiovascular Disorders
Workgroup, O. B. O. T. E. R. O. (., Carrillo-López, N., Martínez-Arias, L., Fernández-Villabrille, S., Ruiz-Torres, M. P., Dusso, A., Cannata-Andía, J. B., Naves-Díaz, M., & Panizo, S. (2021) · Calcified Tissue International · doi:10.1007/s00223-020-00803-2 · Cited by 91
Update in new anabolic therapies for osteoporosis
Canalis, E. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2677 · Cited by 85
Hormonal and systemic regulation of sclerostin
Drake, M. T., & Khosla, S. (2017) · Bone · doi:10.1016/j.bone.2016.12.004 · Cited by 77
Adhikary, S., Choudhary, D., Tripathi, A. K., Karvande, A., Ahmad, N., Kothari, P., & Trivedi, R. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.05.022 · Cited by 47
The Role of Sclerostin in Bone and Ectopic Calcification
De Maré, A., D’Haese, P. C., & Verhulst, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093199 · Cited by 45
Decline in calcitonin receptor expression in osteocytes with age
Gooi, J. H., Chia, L. Y., Walsh, N. C., Karsdal, M. A., Quinn, J. M. W., Martin, T. J., & Sims, N. A. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0524 · Cited by 22
Metadata
- Authors
- Bellido, T., Ali, A. A., Gubrij, I., Plotkin, L. I., Fu, Q., O’Brien, C. A., Manolagas, S. C., & Jilka, R. L.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2005-11-01
- Volume
- 146
- Issue
- 11
- Pages
- 4577-4583
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2149719379
- Cited by
- 641
- References
- 29
- FWCI
- 8.41
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.